$0.76
(Market cap
$95,701 Mln
Revenue (TTM)
$35,484 Mln
P/E Ratio
20.8
P/B Ratio
2
Div. Yield
3.7 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$4,613 Mln
-
ROE
0.1 %
-
ROCE
6.1 %
-
Industry P/E
44.07
-
EV/EBITDA
12.6
-
Debt to Equity
0.6
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
1,283,884,964
10 Years Aggregate
CFO
$62,337.00 Mln
EBITDA
$87,217.00 Mln
Net Profit
$38,845.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| -19.9 | -12.5 | -22.6 | -9.6 | -4.7 | -9.1 | -0.5 |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P 100
| 8.2 | 11.2 | 12.2 | 30.9 | 25.3 | 15.0 | 15.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
| 20.3 | -3.0 | 6.0 | -24.9 | -9.8 | 5.7 | 27.3 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Medtronic PLC (MDT)
|
77.0 | 95,700.8 | 35,484.0 | 4,614.0 | 17.7 | 9.5 | 20.8 | 2.0 |
| 113.3 | 31,498.9 | 7,065.0 | 1,290.0 | 21.8 | 19.4 | 24.6 | 4.7 | |
| 60.4 | 11,507.9 | 4,151.9 | 401.4 | 11.1 | 4.8 | 29.3 | 1.4 | |
| 57.1 | 2,427.7 | 1,334.0 | 97.3 | 14.4 | 11.4 | 14.4 | 2.8 | |
| 1.9 | 6.2 | 0.0 | -8.5 | -89,802.3 | -292.9 | -- | 2.3 | |
| 3.6 | 44.4 | 2.0 | -8.2 | -408.4 | -125.6 | -- | 6.8 | |
| 156.3 | 26,002.5 | 3,195.3 | 908.9 | 21.0 | 13.9 | 29.3 | 3.8 |
Shareholding Pattern
View DetailsAbout Medtronic PLC (MDT)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable... cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland. Address: Building Two, Galway, Ireland Read more
-
Chairman of the Board & CEO
Mr. Geoffrey Straub Martha
-
Chairman of the Board & CEO
Mr. Geoffrey Straub Martha
-
Headquarters
Galway
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Medtronic PLC (MDT)
What is the current share price of Medtronic PLC (MDT) Today?
The share price of Medtronic PLC (MDT) is $76.97 (NYSE) as of 14-May-2026 16:00 EDT. Medtronic PLC (MDT) has given a return of -4.68% in the last 3 years.
What is the current PB & PE ratio of Medtronic PLC (MDT)?
The P/E ratio of Medtronic PLC (MDT) is 20.82 times as on 12-May-2026, a 53 discount to its peers’ median range of 44.07 times.
The P/B ratio of Medtronic PLC (MDT) is 2.00 times as on 12-May-2026, a 31 discount to its peers’ median range of 2.89 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Medtronic PLC (MDT)?
The 52-week high and low of Medtronic PLC (MDT) are Rs 106.33 and Rs 74.40 as of 15-May-2026.
What is the market cap of Medtronic PLC (MDT)?
Medtronic PLC (MDT) has a market capitalisation of $ 95,701 Mln as on 12-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Medtronic PLC (MDT)?
Before investing in Medtronic PLC (MDT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.